Effects of Exercise, Cognitive Training, and Their Combination in Institutionalized Older Adults
NCT07082504, Not applicable, Not yet recruiting, University of Salamanca
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Exercise, Cognitive Training, and Their Combination in Institutionalized Older Adults | ClinicalTrials.gov |
| NCT number | NCT07082504 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 140 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Salamanca | ClinicalTrials.gov |
| Conditions | Aging, Institutionalized Older Adults, Cognitive Abilities, Mobility and Independence, Well-being/Quality of Life | ClinicalTrials.gov |
| Interventions | Physical Exercise Program, Cognitive Stimulation Program, Combined Physical Exercise and Cognitive Stimulation | ClinicalTrials.gov |
| First posted | 2025-07-24 | ClinicalTrials.gov |
| Last updated | 2026-07-10 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from Baseline in Functional Mobility Measured by the Timed Up and Go (TUG) Test at 12 Weeks | From baseline to the end of the intervention at 12 weeks. | Functional mobility will be assessed using the Timed Up and Go (TUG) test. The participant is timed while rising from a chair, walking 3 meters, turning, returning, and sitting. Score: Time in seconds (lower values indicate better mobility). | ClinicalTrials.gov |
| Primary | Change from Baseline in Executive Function Assessed by the Stroop Test at 12 Weeks | From baseline to the end of the intervention at 12 weeks. | Executive function will be assessed using the Stroop Color and Word Test, which evaluates attention, inhibition, and cognitive flexibility. Score: Time (seconds) and error count; lower values indicate better performance. | ClinicalTrials.gov |
| Primary | Change from Baseline in Quality of Life Measured by EQ-5D at 12 Weeks | From baseline to the end of the intervention at 12 weeks. | The EQ-5D assesses five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Score Range: -0.594 to 1. Higher scores indicate better quality of life. | ClinicalTrials.gov |
| Secondary | Change in Balance Performance Measured by the Tinetti Performance Oriented Mobility Assessment (POMA) at 12 Weeks | From baseline to the end of the intervention at 12 weeks. | Balance will be evaluated using the Tinetti POMA. Score Range: 0-28 points. Higher scores indicate better balance and lower risk of falls. | ClinicalTrials.gov |
| Secondary | Change in Lower Body Strength Measured by the 30-Second Chair Stand Test at 12 Weeks | From baseline to the end of the intervention at 12 weeks. | Participants will perform as many full stands as possible from a seated position in 30 seconds. Score: Number of stands. Higher numbers indicate better strength. | ClinicalTrials.gov |
| Secondary | Change in Upper Body Strength Measured by the Arm Curl Test at 12 Weeks | From baseline to 12 weeks post-intervention. | Upper body strength is assessed by the number of bicep curls in 30 seconds using a standardized weight (5 lbs for women, 8 lbs for men). Score: Number of repetitions. Higher scores indicate better strength. | ClinicalTrials.gov |
| Secondary | Change in Grip Strength Measured by Hand Dynamometer at 12 Weeks | From baseline to 12 weeks post-intervention. | Grip strength is measured using a handheld dynamometer. Score: Kilograms (kg). Higher scores indicate stronger grip. | ClinicalTrials.gov |
| Secondary | Change in Sleep Quality Measured by the Pittsburgh Sleep Quality Index (PSQI) at 12 Weeks | From baseline to the end of the intervention at 12 weeks. | SThe PSQI evaluates sleep duration, disturbances, latency, and overall quality. Score Range: 0-21. Lower scores indicate better sleep quality. | ClinicalTrials.gov |
| Secondary | Change in Depressive Symptoms Measured by the Geriatric Depression Scale (GDS) at 12 Weeks | From baseline to the end of the intervention at 12 weeks. | The GDS is a screening tool for depression in older adults. Score Range: 0-15. Lower scores indicate fewer depressive symptoms. | ClinicalTrials.gov |
| Secondary | Change in Life Satisfaction Measured by the Satisfaction With Life Scale (SWLS) at 12 Weeks | From baseline to the end of the intervention at 12 weeks. | The SWLS measures global cognitive judgments of satisfaction with life. Score Range: 5-35. Higher scores indicate greater life satisfaction. | ClinicalTrials.gov |
| Secondary | Change in Functional Mobility Measured by the Timed Up and Go (TUG) Test at 6-Month Follow-Up | From the end of the intervention to 6 months follow-up. | Follow-up assessment of mobility using the TUG test. | ClinicalTrials.gov |
| Secondary | Change in Executive Function Measured by the Stroop Test at 6-Month Follow-Up | From baseline to the end of the intervention at 12 weeks. | Follow-up assessment of executive function using the Stroop Test. | ClinicalTrials.gov |
| Secondary | Change in Quality of Life Measured by the EQ-5D at 6-Month Follow-Up | From end of intervention to 6 months post-intervention. | Follow-up assessment using the EuroQol-5 Dimension (EQ-5D). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)